title: Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.
abstract: In schizophrenia, elevations of serum and CSF S100B levels have been reported and related to state of the disease and negative symptoms. In elderly chronic schizophrenic inpatients with stable medication, S100B may be increased and correlated to psychopathology and neuropsychological deficits. We have measured serum levels of S100B in 41 elderly, chronic schizophrenic patients and 23 age- and gender-matched controls using an immunoluminometric assay. In patients, we assessed detailed psychopathology and neuropsychological performance and determined serum levels of haloperidol, clozapine and its two main metabolites desmethylclozapine and clozapine metabolite N-oxid by HPLC. S100B levels were increased in elderly chronic schizophrenic patients compared to healthy controls. In patients, levels were negatively correlated with deficit symptoms and positively with age. There were no significant differences of S100B between medication groups and no correlation with serum levels of antipsychotics or neuropsychological scores. Elevations of S100B in elderly chronic schizophrenic patients may be related to an active disease process lasting until old-age. Correlations point to the impact of S100B in neuroplasticity and ageing. Post-mortem studies should clarify the presence of altered S100B function in the brain and its relationship to neuroplastic or neurodegenerative processes.
authors.affiliation: Central Institute of Mental Health, P.O. Box 12 21 20, D-68072 Mannheim, Germany. schmitt@zi-mannheim.de
authors.forename: Andrea
authors.initials: A
authors.lastname: Schmitt
authors.forename: Thomas
authors.initials: T
authors.lastname: Bertsch
authors.forename: Uwe
authors.initials: U
authors.lastname: Henning
authors.forename: Heike
authors.initials: H
authors.lastname: Tost
authors.forename: Ansgar
authors.initials: A
authors.lastname: Klimke
authors.forename: Fritz A
authors.initials: FA
authors.lastname: Henn
authors.forename: Peter
authors.initials: P
authors.lastname: Falkai
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000097:blood / Q000627:therapeutic use; D002908:Chronic Disease; D003024:Clozapine / Q000097:blood / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis* / Q000209:etiology; D003865:Major Depressive Disorder / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D006220:Haloperidol / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000097:blood* / Q000134:cerebrospinal fluid; D009483:Neuropsychological Tests; D011581:Psychological Tests; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood* / Q000134:cerebrospinal fluid; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index
chemical_list: D014150:Antipsychotic Agents; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human; D003024:Clozapine; D006220:Haloperidol